Nucleic acid drug targeting MURF1
AssigneeShionogi & Co., Ltd.
InventorsTakahiro Fujiwara, Kazuyoshi Tomita, Kunitaka Nashiki, Ayumi Nagasawa, Ryo Yoshimoto, Takahito Ito
Life of this patent
Estimating the term…
Abstract
It was found that nucleic acids for the specific targeting sequences or nucleic acids having the specific sequences have superior suppression activities of MURF1 expression. Pharmaceutical compositions including the nucleic acids as active ingredient are useful for treating or preventing disease accompanied by one or more symptoms selected from the group consisting of decrease in muscle mass, decrease in muscle strength and muscle dysfunction.
Claims11
A nucleic acid suppressing the expression of MURF1 comprising an oligonucleotide consisting of 15 to 30 nucleotides having at least 15 bases or more complementary to the base sequence consisting of positions 1427 to 1447 of SEQ ID NO:
- 609.
A nucleic acid comprising the base sequence of SEQ ID NO:
- 482 or 484;
- the base sequence of SEQ ID NO:
- 482 wherein 1 to 3 bases are deleted, substituted or inserted at positions 2 to 18;
- or
- the base sequence of SEQ ID NO:
- 484 wherein 1 to 3 bases are deleted, substituted or inserted;
- and suppressing the expression of MURF1.
A double-stranded nucleic acid comprising any of the following combinations:
- an oligonucleotide consisting of the base sequence of SEQ ID NO:
- 481 or 636 and an oligonucleotide consisting of the base sequence of SEQ ID NO:
- 482, or
- an oligonucleotide consisting of the base sequence of SEQ ID NO:
- 483 or 637 and an oligonucleotide consisting of the base sequence of SEQ ID NO:
- 484.
Dependencies are inferred from the claim text.